{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:45:16Z","timestamp":1785897916604,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":103,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gilead HIV\/HCV No Co-Infection (NoCo) Request for Proposal (RFP) Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-026-01463-5","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:53:48Z","timestamp":1777042428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel model of care; Telemedicine and peer support for HCV care among HIV-infected people who inject drugs in remote Myanmar: a retrospective study"],"prefix":"10.1186","volume":"23","author":[{"given":"Ni Ni","family":"Tun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Smithuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyan Lynn","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo Min Min","family":"Hteik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinne","family":"Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefien","family":"van Olmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"1463_CR1","unstructured":"United Nations Office on Drugs and Crime: World Drug Report. 2025. Available from https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2025.html. Accessed 14 Feb 2026."},{"issue":"1","key":"1463_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"J Grebely","year":"2018","unstructured":"Grebely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2018;114(1):150\u201366. https:\/\/doi.org\/10.1111\/add.14393.","journal-title":"Addiction"},{"key":"1463_CR3","unstructured":"World Health Organization .Global HIV, Hepatitis and STIs Programmes: People who inject drugs. 2020. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/populations\/people-who-inject-drugs. Accessed 10 Oct 2024."},{"key":"1463_CR4","unstructured":"Joint United Nations Programme on HIV\/AIDS. Myanmar Country Data. 2023. Available from https:\/\/www.aidsdatahub.org\/resource\/myanmar-country-data-2023. Accessed 10 Oct 2024."},{"key":"1463_CR5","unstructured":"National Hepatitis Control Program. Ministry of Health and Sports, Myanmar. National Strategic Plan on Viral Hepatitis 2016\u20132020. Available from: https:\/\/www.aidsdatahub.org\/resource\/myanmar-national-strategic-plan-viral-hepatitis-2016-2020. Accessed 10 Oct 2024."},{"issue":"10","key":"1463_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1086\/644771","volume":"49","author":"TY Chen","year":"2009","unstructured":"Chen TY, Ding EL, Seage IGR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49(10):1605\u201315. https:\/\/doi.org\/10.1086\/644771.","journal-title":"Clin Infect Dis"},{"key":"1463_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-021-00921-5","volume":"11","author":"J Jia","year":"2022","unstructured":"Jia J, Zhu Q, Deng L, et al. Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study. Infect Dis Poverty. 2022;11:7. https:\/\/doi.org\/10.1186\/s40249-021-00921-5.","journal-title":"Infect Dis Poverty"},{"key":"1463_CR8","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273174\/9789241550345-eng.pdf?ua=1. Accessed 10 Oct 2024."},{"issue":"9","key":"1463_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for Hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348. https:\/\/doi.org\/10.7326\/M16-2575.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1463_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40121-018-0228-8","volume":"8","author":"RM Murdock","year":"2019","unstructured":"Murdock RM, Brizzi MB, Perez O, Badowski ME. Public health considerations among people who inject drugs with HIV\/HCV co-infection: a review. Infect Dis Ther. 2019;8(1):23\u201332. https:\/\/doi.org\/10.1007\/s40121-018-0228-8.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1463_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","volume":"72","author":"B Hajarizadeh","year":"2020","unstructured":"Hajarizadeh B, Cunningham EB, Valerio H, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.012.","journal-title":"J Hepatol"},{"issue":"1","key":"1463_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11904-010-0071-3","volume":"8","author":"EA Operskalski","year":"2011","unstructured":"Operskalski EA, Kovacs A. HIV\/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV\/AIDS Rep. 2011;8(1):12\u201322. https:\/\/doi.org\/10.1007\/s11904-010-0071-3.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"11","key":"1463_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.drugpo.2015.07.016","volume":"26","author":"N Luhmann","year":"2015","unstructured":"Luhmann N, Champagnat J, Golovin S, Maistat L, Agustian E, Inaridze I, et al. Access to hepatitis C treatment for people who inject drugs in low- and middle-income settings: evidence from 5 countries in Eastern Europe and Asia. Int J Drug Policy. 2015;26(11):1081\u20137. https:\/\/doi.org\/10.1016\/j.drugpo.2015.07.016.","journal-title":"Int J Drug Policy"},{"key":"1463_CR14","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 2014. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/128048\/1\/9789241507431_eng.pdf?ua=1. Accessed 10 Oct 2024."},{"key":"1463_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-10-7","volume":"10","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7. https:\/\/doi.org\/10.1186\/1477-7517-10-7.","journal-title":"Harm Reduct J"},{"key":"1463_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00743-8","volume":"20","author":"M Di Ciaccio","year":"2023","unstructured":"Di Ciaccio M, Villes V, Perfect C, et al. Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey. Harm Reduct J. 2023;20:15. https:\/\/doi.org\/10.1186\/s12954-023-00743-8.","journal-title":"Harm Reduct J"},{"key":"1463_CR17","unstructured":"National Hepatitis Control Program. Ministry of Health and Sports. Myanmar. Simplified Treatment Guidelines for Hepatitis C infection: Myanmar. 2017. Available from: https:\/\/www.aidsdatahub.org\/resource\/simplified-treatment-guidelines-hepatitis-c-infection-myanmar. Accessed 10 Oct 2024."},{"issue":"9","key":"1463_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26355","volume":"27","author":"N Tun","year":"2024","unstructured":"Tun N, Oo CL, Nwe CM, Lynen L, Decroo T, Smithuis F, et al. Improving access to integrated community-based HIV, HCV and harm reduction services for people who inject drugs in Putao district, North Myanmar. J Int AIDS Soc. 2024;27(9):e26355. https:\/\/doi.org\/10.1002\/jia2.26355.","journal-title":"J Int AIDS Soc"},{"key":"1463_CR19","unstructured":"United Nations Office on Drugs and Crime Southeast Asia Opium Survey 2023. Cultivation, Production, and Implications. Available from https:\/\/www.unodc.org\/roseap\/uploads\/documents\/Publications\/2023\/Southeast_Asia_Opium_Survey_2023.pdf. Accessed 10 Oct 2024."},{"key":"1463_CR20","unstructured":"Joint United Nations Programme on HIV\/AIDS. Community members are driving the AIDS response in northern Myanmar. 2020. Available from: https:\/\/www.unaids.org\/en\/resources\/presscentre\/featurestories\/2020\/march\/20200326_myanmar. Accessed 10 Oct 2024."},{"issue":"1","key":"1463_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1172-x","volume":"16","author":"ARD McLean","year":"2018","unstructured":"McLean ARD, Wai HP, Thu AM, et al. Malaria elimination in remote communities requires integration of malaria control activities into general health care: an observational study and interrupted time series analysis in Myanmar. BMC Med. 2018;16(1):183. https:\/\/doi.org\/10.1186\/s12916-018-1172-x.","journal-title":"BMC Med"},{"issue":"17","key":"1463_CR22","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMra2403308","volume":"393","author":"L Castera","year":"2025","unstructured":"Castera L, Rinella ME, Tsochatzis EA. Noninvasive assessment of liver fibrosis. N Engl J Med. 2025;393(17):1715\u201329. https:\/\/doi.org\/10.1056\/NEJMra2403308.","journal-title":"N Engl J Med"},{"issue":"4","key":"1463_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/hiv.12711","volume":"20","author":"S Amele","year":"2019","unstructured":"Amele S, Peters L, Sluzhynska M, EuroSIDA study group, et al. Establishing a hepatitis C continuum of care among HIV\/hepatitis C virus-co-infected individuals in EuroSIDA. HIV Med. 2019;20(4):264\u201373. https:\/\/doi.org\/10.1111\/hiv.12711.","journal-title":"HIV Med"},{"key":"1463_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100178","volume":"8","author":"Y Aponte-Mel\u00e9ndez","year":"2023","unstructured":"Aponte-Mel\u00e9ndez Y, Mateu-Gelabert P, Eckhardt B, et al. Hepatitis C virus care cascade among people who inject drugs in Puerto Rico: minimal HCV treatment and substantial barriers to HCV care. Drug Alcohol Depend Rep. 2023;8:100178. https:\/\/doi.org\/10.1016\/j.dadr.2023.100178.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"22","key":"1463_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192215237","volume":"19","author":"N Bar","year":"2022","unstructured":"Bar N, Bensoussan N, Rabinowich L, et al. Barriers and facilitators of Hepatitis C care in persons co-infected with Human Immunodeficiency Virus. Int J Environ Res Public Health. 2022;19(22):15237. https:\/\/doi.org\/10.3390\/ijerph192215237.","journal-title":"Int J Environ Res Public Health"},{"key":"1463_CR26","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Hepatitis C: new models of care for drugs services. 2019. Available from: http:\/\/www.emcdda.europa.eu\/system\/files\/attachments\/11482\/Hepatitis-C-new-models-of-care-for-drugs-services_WEB.pdf"},{"issue":"1","key":"1463_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/jvh.13405","volume":"28","author":"Y Min Thaung","year":"2021","unstructured":"Min Thaung Y, Chasela CS, Chew KW, et al. Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and\/or hepatitis B virus-co-infected patients in Myanmar. J Viral Hepat. 2021;28(1):147\u201358. https:\/\/doi.org\/10.1111\/jvh.13405.","journal-title":"J Viral Hepat"},{"issue":"6","key":"1463_CR28","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/liv.14849","volume":"41","author":"CY Chen","year":"2021","unstructured":"Chen CY, Huang CF, Cheng PN, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021;41(6):1265\u201377. https:\/\/doi.org\/10.1111\/liv.14849.","journal-title":"Liver Int"},{"key":"1463_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6054677","volume":"2022","author":"TTP Nguyen","year":"2022","unstructured":"Nguyen TTP, Ngo TQM, Pham VL, Nguyen VH, Nguyen TH. Determination of risk factors associated with the failure of 12 weeks of direct-acting antiviral therapy in patients with hepatitis C: a prospective study. Biomed Res Int. 2022;2022:6054677. https:\/\/doi.org\/10.1155\/2022\/6054677.","journal-title":"Biomed Res Int"},{"issue":"10","key":"1463_CR30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/hiv.13681","volume":"25","author":"D Basoulis","year":"2024","unstructured":"Basoulis D, Mastrogianni E, Eliadi I, Papadopoulou M, Psichogiou M. HCV-HIV co-infection in people who inject drugs: barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece. HIV Med. 2024;25(10):1135\u201344. https:\/\/doi.org\/10.1111\/hiv.13681.","journal-title":"HIV Med"},{"issue":"11","key":"1463_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","volume":"3","author":"B Hajarizadeh","year":"2018","unstructured":"Hajarizadeh B, Cunningham EB, Reid H, et al. Direct-acting antiviral treatment for Hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754\u201367. https:\/\/doi.org\/10.1016\/S2468-1253(18)30304-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"1463_CR32","first-page":"1881","volume":"58","author":"BC Zanoni","year":"2014","unstructured":"Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. Clin Infect Dis. 2014;58(12):1881\u20134.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1463_CR33","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/cid\/ciab1071","volume":"75","author":"CY Cheng","year":"2022","unstructured":"Cheng CY, Ki Cunningham EB, et al. Reinfection following successful direct-acting antiviral therapy among people who inject drugs: pooled analysis of the SIMPLIFY and D3FEAT studies. Clin Infect Dis. 2022;75(9):1543\u201350. https:\/\/doi.org\/10.1093\/cid\/ciab1071.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1463_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0123","volume":"7","author":"AH Litwin","year":"2024","unstructured":"Litwin AH, et al. Long-term follow-up of hepatitis C treatment outcomes and reinfection among people who inject drugs (HERO study). JAMA Netw Open. 2024;7(3):e240123. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.0123.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"1463_CR35","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/cid\/ciz693","volume":"70","author":"J Grebely","year":"2020","unstructured":"Grebely J, et al. Hepatitis C reinfection after successful DAA therapy among people who inject drugs: multi-site cohort analyses. Clin Infect Dis. 2020;70(11):2355\u201363. https:\/\/doi.org\/10.1093\/cid\/ciz693.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1463_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jhep.2022.05.010","volume":"77","author":"EB Cunningham","year":"2022","unstructured":"Cunningham EB, Hajarizadeh B, et al. Hepatitis C reinfection after successful treatment among people who inject drugs: systematic review and meta-analysis. J Hepatol. 2022;77(4):1015\u201327. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.010.","journal-title":"J Hepatol"},{"key":"1463_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.103959","author":"MJ Akiyama","year":"2023","unstructured":"Akiyama MJ, Riback LR, Nyakowa M, et al. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya. Int J Drug Policy. 2023. https:\/\/doi.org\/10.1016\/j.drugpo.2023.103959.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01463-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01463-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01463-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:59:50Z","timestamp":1785895190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01463-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01463-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5238109\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"125"}}